Restricted
For patients with COVID-19 disease within 24 hours of ICU admission and who require ventilation or high-flow oxygen
Known hypersensitivity to tocilizumab or any component of the formulation
LFTs
CBC
Hypersensitivity
Refer to COVID-19 Treatment Algorithm
Neutropenia, anemia
Hepatotoxicity
Hypersensitivity
Risk of infection
May enhance the immunosuppressive effect of other immunosuppressants
Do not administer to patients with active bacterial infections
Avoid in pregnancy
Preparation
Administration
Diluent
Mechanism of action: Interleukin-6 (IL-6) receptor antagonist leading to reduced cytokines and acute phase reactant production
Average half-life: 11-13 days
Median time to onset: Reduced cytokines in 4 hours
Adapted from the AdventHealth Kansas City Antimicrobial Stewardship Program